New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma

被引:26
作者
Adams, H. [1 ]
Tzankov, A. [1 ]
Lugli, A. [1 ]
Zlobec, I. [1 ]
机构
[1] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
关键词
GROWTH-FACTOR RECEPTOR; COLORECTAL-CANCER; BREAST-CANCER; STAINING INTENSITY; TISSUE MICROARRAY; P53; EXPRESSION; SURVIVAL; FOXP1; ACTIVATION; CARCINOMA;
D O I
10.1136/jcp.2008.059063
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Aims: Receiver operating characteristic (ROC) curve analysis is a well-established method to study the accuracies of biological markers. It may, however, be suboptimal for analysing outcomes over time, such as prognosis. Here, the clinical value of time-dependent ROC curve analysis for improving the identification of high-risk patients with colon cancers and diffuse large B-cell lymphomas (DLBCL) is explored. Methods: Using tissue microarrays, immunohistochemistry was performed on two matched sets (N = 469, each) of colon cancers (p53, CD8(+) tumour infiltrating lymphocytes (TILs), mammalian sterile-like 20 kinase 1 (MST1), mucin 2 (MUC2) and urokinase plasminogen activator receptor (uPAR)) and on 208 DLBCL (Bcl2, Bcl6, CD10, FOXP1 and Ki67). The area-under-the-curve (AUC)-over-time plots, cut-off scores for tumour marker positivity and Kaplan-Meier survival curves were analysed. Results: With the exception of uPAR, all markers were most accurate within the first 18 months following diagnosis. Expression of p53 (AUC = 0.75), uPAR (AUC = 0.64), Bcl2 (AUC = 0.58) and FOXp1 (AUC = 0.68) was linked to more aggressive tumours, while TILs (AUC = 0.38), MST1 (AUC = 0.39), MUC2 (AUC = 0.38), Bcl6 (AUC = 0.4), CD10 (AUC = 0.49) and Ki67 (AUC = 0.41) were predictive of improved survival. Cut-off scores for markers at their peak accuracies as well as survival time differences were reproducible between colon cancer groups. Only FOXp1 at its optimal cut-off of 60% had significant effects on survival in DLBCL (p = 0.019). Conclusions: Time-dependent ROC curve analysis is a novel tool for identifying potential immunohistochemical prognostic markers across varying follow-up times. Use of this tool could facilitate the identification of high-risk patients not only with colon cancer and DLBCL but with a range of other tumour types.
引用
收藏
页码:986 / 997
页数:12
相关论文
共 45 条
[1]
MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas [J].
Ajioka, Y ;
Watanabe, H ;
Jass, JR .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (05) :417-421
[2]
Evolving role of uPA/uPAR system in human cancers [J].
Ass, Kathleen ;
Ahmad, Aamir ;
Azmi, Asfar S. ;
Sarkar, Sarah H. ;
Sarkar, Fazlul H. .
CANCER TREATMENT REVIEWS, 2008, 34 (02) :122-136
[3]
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections [J].
Atkins, D ;
Reiffen, KA ;
Tegtmeier, CL ;
Winther, H ;
Bonato, MS ;
Störkel, S .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) :893-901
[4]
Banham AH, 2005, CLIN CANCER RES, V11, P1065
[5]
Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome [J].
Barrans, SL ;
Fenton, JAL ;
Banham, A ;
Owen, RG ;
Jack, AS .
BLOOD, 2004, 104 (09) :2933-2935
[7]
Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL [J].
Brown, Philip J. ;
Ashe, Sally L. ;
Leich, Ellen ;
Burek, Christof ;
Barrans, Sharon ;
Fenton, James A. ;
Jack, Andrew S. ;
Pulford, Karen ;
Rosenwald, Andreas ;
Banham, Alison H. .
BLOOD, 2008, 111 (05) :2816-2824
[8]
EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder [J].
Brunner, A. ;
Prelog, M. ;
Verdorfer, I. ;
Tzankov, A. ;
Mikuz, G. ;
Ensinger, C. .
JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (03) :307-310
[9]
Buzdar AU, 1998, CLIN CANCER RES, V4, P527
[10]
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810